Lupin is currently trading at Rs. 1061.35, up by 8.90 points or 0.85% from its previous closing of Rs. 1052.45 on the BSE.
The scrip opened at Rs. 1059.80 and has touched a high and low of Rs. 1074.55 and Rs. 1051.45 respectively. So far 78174 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1121.85 on 18-Sep-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 1086.95 and Rs. 1048.05 respectively. The current market cap of the company is Rs. 48308.49 crore.
The promoters holding in the company stood at 46.88%, while Institutions and Non-Institutions held 40.05% and 12.79% respectively.
Lupin’s wholly-owned subsidiary -- Lupin Pharmaceuticals Inc, is recalling 46,479 bottles of anti-viral medication Oseltamivir Phosphate for Oral Suspension in the American market. The company has initiated the recall of the affected lot due to ‘Failed Impurities/Degradation Specifications’. The product has been manufactured at Lupin's Aurangabad (Maharashtra) based manufacturing plant. The company initiated the recall, which the US health regulator has classified as Class III, on January 21 this year.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
